Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets Size & Share to 2021 - PowerPoint PPT Presentation

Loading...

PPT – Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets Size & Share to 2021 PowerPoint presentation | free to download - id: 7ec086-MjE0N



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets Size & Share to 2021

Description:

Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets. Enquiry @ – PowerPoint PPT presentation

Number of Views:55

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets Size & Share to 2021


1
Type 2 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021
No. Pages 179
Published on July - 2015
2
.
Report Overview
About Type 2 Diabetes Mellitus Therapeutics in
Major Developed Markets to 2021 Research Beam
added a report Type 2 Diabetes Mellitus
Therapeutics in Major Developed Markets to 2021.
Type 2 Diabetes Mellitus Therapeutics in Major
Developed Markets to 2021 - Strong Pipeline and
Expanding Treatment Population to Encourage
Robust Growth Summary  Type 2 Diabetes Mellitus
(T2DM) is a metabolic disease characterized by
chronic hyperglycemia (high blood glucose
levels). Global prevalence has risen rapidly in
the past several decades, particularly in line
with obesity. This has been attributed to a range
of factors, including economic development,
increasing urbanization, aging populations, and
changes in lifestyle patterns such as reduced
levels of physical activity and consumption of
higher-calorie diets. Get Full Details On
http//www.researchbeam.com/type-2-diabetes-mellit
us-therapeutics-in-major-developed-to-2021-strong-
pipeline-and-expanding-treatment-population-to-enc
ourage-robust-growth-market
3
.
Report Overview
This has led to strong commercial interest in the
development of T2DM therapeutics. The current
market is large and diverse, comprising several
drug classes, including generic and branded
drugs. Owing to the range of therapeutic options
available, the treatment algorithm is complex.
However, current treatment regimens are often
associated with limited long-term efficacy,
complex and inconvenient dosing regimens, and
undesirable side effects such as weight gain and
hypoglycemia (low blood glucose
levels).  Scope  - Metformin monotherapy will
remain the first-line pharmacotherapy for T2DM. -
The emergence of several new drug classes over
the past decade, namely the Glucagon-Like
Peptide-1 (GLP-1) receptor agonists, Dipeptidyl
Peptidase 4 (DPP-4) inhibitors, and
SodiumGlucose Cotransporter 2 (SGLT-2)
inhibitors, has led to considerable market
growth. - Which products lead these drug classes
and what threats do they face from the
pipeline? - How will the continued uptake of
newer drug classes impact established drug
classes such as the sulfonylureas and
thiazolidinedione's?
4
.
Report Overview
  • - Leading insulin therapy Lantus (insulin
    glargine) recently lost patent protection in most
    major markets.
  • - Will recently approved insulin therapies such
    as Tresiba (insulin degludec) and Toujeo (insulin
    glargine) be able to capture a significant
    portion of Lantus market share?
  • - The pipeline is large and highly innovative,
    comprising a range of molecule types and
    molecular targets.
  • - How do different molecule types and molecular
    targets compare in terms of average failure rate,
    clinical trial duration, and clinical trial size?
  • - Which late-stage pipeline molecules show the
    most promise and how will they impact the
    treatment algorithm over the forecast period?
  • - Which late-stage pipeline molecules are
    expected to generate the highest revenues?
  • - Over the 20142021 forecast period, the global
    T2DM market is expected to increase in value at a
    CAGR of 7.5 from 23.5 billion to 39.0 billion.
  • - How do prevalence, diagnosis, and treatment
    patterns vary in the eight major markets?

5
Report Overview
  • - Which factors will drive market growth most
    significantly?
  • - Strategic consolidation activity in T2DM is
    considerable, with US-based companies being key
    players.
  • Do T2DM products tend to attract high levels of
    investment?
  • Reasons to buy
  •  
  • - Understand the clinical context of the T2DM
    indication and the global burden of the disease
    by considering epidemiology, symptoms, etiology,
    pathophysiology, co-morbidities and
    complications, disease classification, disease
    prognosis, and treatment options
  • - Appreciate the current T2DM marketed products
    landscape, including the dominant therapeutic
    strategies, products, and companies, and
    recognize gaps within the market and areas of
    unmet need
  • - Identify key pipeline trends in molecule type
    and molecular target
  • - Recognize the late-stage pipeline molecules
    that have demonstrated strong therapeutic
    potential in T2DM by examining clinical trial
    data and multi-scenario product forecast
    projections
  •  

6
Report Overview
  • - Consider market opportunities and potential
    risks by examining trends in T2DM clinical trial
    size, duration, and failure rate by phase of
    development, molecule type, and molecular target
  • - Discern variances in treatment usage patterns,
    annual therapy costs, and market growth
    projections for the US, Canada, the UK, France,
    Germany, Italy, Spain, and Japan
  • - Discover how strategic consolidations have
    shaped the current T2DM pipeline and marketed
    products landscapes
  •  

7
Table Of Contents
1 Table of Contents1 Table of Contents 41.1
List of Tables 71.2 List of Figures 72
Introduction 92.1 Disease Overview 92.2
Epidemiology 92.3 Symptoms 102.4 Etiology
102.5 Pathophysiology 112.6 Co-morbidities and
Complications 132.7 Classification 152.8
Prognosis 152.9 Diagnosis 16
8
Table Of Contents
2.10 Assessing Treatment Effectiveness 172.11
Treatment Algorithm 172.12 Non-insulin T2DM
Therapies 192.12.1 Biguanides 192.12.2
Sulfonylureas and Meglitinides 19 2.12.3
Thiazolidinediones 202.12.4 Glucagon-Like
Peptide-1 (GLP-1) Receptor Agonists and
Dipeptidyl Peptidase 4 (DPP-4) Inhibitors
202.12.5 Sodiuma Glucose Linked Transporter-2
(SGLT-2) Inhibitors 212.12.6 Other Non-insulin
Therapies 21Enquiry about this report _at_
http//www.researchbeam.com/type-2-diabetes-mellit
us-therapeutics-in-major-developed-to-2021-strong-
pipeline-and-expanding-treatment-population-to-enc
ourage-robust-growth-market/enquire-about-report

9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/type-2-diabetes-mellit
us-therapeutics-in-major-developed-to-2021-strong-
pipeline-and-expanding-treatment-population-to-enc
ourage-robust-growth-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE 1 (800) 910-6452 E-MAIL
sales_at_researchbeam.com
About PowerShow.com